Zhen Kun Yang1, Ying Shen1, Wei Feng Shen2, Li Jin Pu3, Hua Meng3, Rui Yan Zhang1, Qi Zhang1, Qiu Jing Chen3, Raffaele De Caterina4, Lin Lu5. 1. Department of Cardiology, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, People's Republic of China. 2. Department of Cardiology, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, People's Republic of China; Institute of Cardiovascular Diseases, Shanghai Jiaotong University School of Medicine, Shanghai 200025, People's Republic of China. 3. Institute of Cardiovascular Diseases, Shanghai Jiaotong University School of Medicine, Shanghai 200025, People's Republic of China. 4. "G. d'Annunzio University", Chieti, Italy; Fondazione "G. Monasterio", Pisa, Italy. Electronic address: rdecater@unich.it. 5. Department of Cardiology, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, People's Republic of China; Institute of Cardiovascular Diseases, Shanghai Jiaotong University School of Medicine, Shanghai 200025, People's Republic of China. Electronic address: lulin1965@yahoo.com.cn.
Abstract
BACKGROUND AND AIM: Glycated albumin (GA) and the endogenous secretory receptor for advanced glycation endproducts (esRAGE) may modulate risk related to atherosclerosis. We tested the hypothesis that elevated GA and reduced esRAGE in serum are associated with adverse clinical outcomes in patients with type 2 diabetes and stable coronary artery disease (CAD). METHODS: We determined GA and esRAGE serum levels in 576 consecutive patients with type 2 diabetes and stable CAD undergoing sirolimus-eluting stent (SES)-PCI. The primary endpoint was the incidence of major adverse cardio-cerebral events (MACCE) including cardiac death, non-fatal myocardial infarction, and non-fatal stroke during a 2-year follow-up. The secondary endpoint was the occurrence of clinically driven repeat revascularization during a 2-year follow-up. The prognostic value of GA and esRAGE was determined with the Cox-proportional hazard model after adjustment for covariates. RESULTS: A total 40 patients (6.9%) experienced MACCE, and 108 (18.8%) patients underwent repeat coronary revascularization during the follow-up. Serum GA (HR=1.22, 95% CI 1.16-1.28; HR=1.15, 95% CI 1.11-1.19, respectively; for both p<0.001) and esRAGE (HR=0.60, 95% CI 0.40-0.87; HR=0.75, 95% CI 0.61-0.92, respectively; for both p<0.01) levels remained independent predictors of the primary and secondary endpoints after adjustment for possible confounders. CONCLUSIONS: Serum GA and esRAGE are novel predictors of long-term clinical outcomes in patients with type 2 diabetes and stable CAD. Increased serum GA and decreased esRAGE are associated with a poor prognosis in such patients.
BACKGROUND AND AIM: Glycated albumin (GA) and the endogenous secretory receptor for advanced glycation endproducts (esRAGE) may modulate risk related to atherosclerosis. We tested the hypothesis that elevated GA and reduced esRAGE in serum are associated with adverse clinical outcomes in patients with type 2 diabetes and stable coronary artery disease (CAD). METHODS: We determined GA and esRAGE serum levels in 576 consecutive patients with type 2 diabetes and stable CAD undergoing sirolimus-eluting stent (SES)-PCI. The primary endpoint was the incidence of major adverse cardio-cerebral events (MACCE) including cardiac death, non-fatal myocardial infarction, and non-fatal stroke during a 2-year follow-up. The secondary endpoint was the occurrence of clinically driven repeat revascularization during a 2-year follow-up. The prognostic value of GA and esRAGE was determined with the Cox-proportional hazard model after adjustment for covariates. RESULTS: A total 40 patients (6.9%) experienced MACCE, and 108 (18.8%) patients underwent repeat coronary revascularization during the follow-up. Serum GA (HR=1.22, 95% CI 1.16-1.28; HR=1.15, 95% CI 1.11-1.19, respectively; for both p<0.001) and esRAGE (HR=0.60, 95% CI 0.40-0.87; HR=0.75, 95% CI 0.61-0.92, respectively; for both p<0.01) levels remained independent predictors of the primary and secondary endpoints after adjustment for possible confounders. CONCLUSIONS: Serum GA and esRAGE are novel predictors of long-term clinical outcomes in patients with type 2 diabetes and stable CAD. Increased serum GA and decreased esRAGE are associated with a poor prognosis in such patients.
Authors: Stephanie J Loomis; Yuan Chen; David B Sacks; Eric S Christenson; Robert H Christenson; Casey M Rebholz; Elizabeth Selvin Journal: Clin Chem Date: 2017-03-09 Impact factor: 8.327
Authors: Mary R Rooney; Natalie Daya; Olive Tang; John William McEvoy; Josef Coresh; Robert H Christenson; Elizabeth Selvin Journal: Clin Chem Date: 2022-03-04 Impact factor: 8.327
Authors: Craig Basman; Sarah L Fishman; Dimiter Avtanski; Umar Rashid; Arber Kodra; Karin Chen; Rebecca Jonas; Guillaume J Stoffels; Martin Lesser; Damian Inlall; Karina Ziskovich; Varinder Singh; Leonid Poretsky Journal: Metabol Open Date: 2020-08-16
Authors: Run Du; Rui Yan Zhang; Lin Lu; Ying Shen; Li Jin Pu; Zheng Bin Zhu; Qi Zhang; Jian Hu; Zhen Kun Yang; Feng Hua Ding; Jian Sheng Zhang; Wei Feng Shen Journal: Cardiovasc Diabetol Date: 2018-11-27 Impact factor: 9.951
Authors: James B Young; Marjolaine Gauthier-Loiselle; Robert A Bailey; Ameur M Manceur; Patrick Lefebvre; Morris Greenberg; Marie-Hélène Lafeuille; Mei Sheng Duh; Brahim Bookhart; Carol H Wysham Journal: Cardiovasc Diabetol Date: 2018-08-24 Impact factor: 9.951